Estimates Revisions Exelixis, Inc. Berne S.E.
Stocks
EX9
US30161Q1040
Biotechnology & Medical Research
|
End-of-day quote
Berne S.E.
2026-09-30
|
5-day change | 1st Jan Change | ||
| 50.33 CHF | +4.05% |
|
+3.74% | - |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Exelixis, Inc.(EXEL)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Exelixis, Inc.(EXEL)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Exelixis, Inc.(EXEL)
EBIT
Dividend / Share (DPS)
Data source:
Exelixis, Inc.(EXEL)
Cash or Net Debt
- Stock Market
- Stocks
- EXEL Stock
- EX9 Stock
- Consensus Exelixis, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
